Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

crenezumab

Bristol-Myers Squibb (BMS) building

BMS chases after Roche in EU bladder cancer race

Opdivo set to go head-to-head with Tecentriq

- PMLiVE

Global pharma market forecast to reach $1.12tr by 2022

Annual growth of 6.3 per cent expected and biologics are set to occupy a stronger position

- PMLiVE

Merck closes in on first-line NSCLC label for Keytruda in US

Accelerated FDA review could see PD-1 inhibitor approved by the end of the year

Roche Basel Switzerland

Roche’s melanoma combo “too expensive” for NHS use, says NICE

Cost-effectiveness body rejects Cotellic/Zelboraf despite acknowledging survival benefits

Roche Basel Switzerland

Roche’s checkpoint inhibitor Tecentriq aces lung cancer trial

Second-line therapy showed overall survival benefit irrespective of PD-L1 status

Roche - Basel

Roche re-joins UK pharma’s trade body the ABPI

Firm left in 2009 following its suspension for a major Code of Practice breach 

- PMLiVE

Boehringer to add wireless data-collection to its Respimat inhaler

Joins forces with Qualcomm for COPD adherence collaboration

Novartis day

Novartis drug works in secondary progressive MS

Orally-active siponimod reduces risk of disability progression

- PMLiVE

AbbVie’s venetoclax set for early access in UK

Drug for CLL patients included in EAMS by MHRA

- PMLiVE

Lupus trial hailed as a success despite patient deaths

Phase IIb trial of Aurinia Pharmaceuticals’ voclosporin met its objective

Biogen Idec building

Biogen buys into Ionis’ nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 

- PMLiVE

Controversial new CDF promises “clearer, faster decision-making”

However, pharma companies and charities remain concerned over pricing and access

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links